Blake Lee Neubauer

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Lawrence M. Gelbert, Shufen Cai, Xi Lin et al. · Investigational New Drugs · 2014 · 565 citations · Full text

Medicine, Oncology, Pharmacology +17

The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts

Jeremy R. Graff, Ann M. McNulty, Kimberly R. Hanna et al. · Cancer Research · 2005 · 437 citations · Full text

Medicine, Oncology, Pharmacology +15

Increased AKT Activity Contributes to Prostate Cancer Progression by Dramatically Accelerating Prostate Tumor Growth and Diminishing p27Kip1 Expression

Jeremy R. Graff, Bruce W. Konicek, Ann M. McNulty et al. · Journal of Biological Chemistry · 2000 · 380 citations · Full text

Medicine, Molecular Biology, Oncology +15

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

Jeremy R. Graff, Bruce W. Konicek, Thomas M. Vincent et al. · Journal of Clinical Investigation · 2007 · 379 citations · Full text

Medicine, Cancer Biology, Oncology +17

Epithelial-mesenchymal interactions in prostatic development. I. morphological observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder.

Gerald R. Cunha, H Fujii, Blake Lee Neubauer et al. · The Journal of Cell Biology · 1983 · 290 citations · Full text

Life Sciences, Cell Biology, Developmental Biology +16